Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense Technologies Featured in Multiple Presentations at Upcoming Imaging Conference

Cell imaging labels, V-Sense and Cell Sense, both the subject of multi-institutional studies being presented at upcoming ISMRM meeting

April 15, 2009 - Pittsburgh, Pennsylvania

Celsense, Inc. announced today that its technologies are featured in at least three studies being presented at the upcoming ISMRM (International Society for Magnetic Resonance in Medicine) conference being held in Honolulu, HI, April 28-24. 

Imaging in vivo inflammatory response
Preliminary results from one of the studies being presented indicates that the V-Sense 19F-based nanoemulsion is a specific in vivo biomarker for inflammation that can potentially be used to quantify macrophage activity. 

Accumulation of monocytes/macrophages is the hallmark of chronic inflammation. Researchers used the V-Sense 19F MRI to monitor this response non-invasively, in vivo, detect an inflammatory response in a sponge granuloma model, and identified the types of cells involved in this response using Fluorescence Activated Cell Sorting (FACS).

Simultaneous detection of differently labeled cells in vivo
Another presentation will review data demonstrating the feasibility of using V-Sense to distinguish between differently labeled cells in vivo.

Previous studies showed that perfluorocarbon (PFC) emulsions like V-Sense can be taken up by macrophages, B-cells and dendritic cells thus leaving the possibility of in vivo tracking and quantification of different immune cells within a single multi-color 19F CSI experiment. 

This pilot study showed the ability to distinguish between cells labeled with different fluorine markers in a PT mouse model using fast and specific multi-color chemical shift imaging (CSI) methods thus leading to the conclusion that multi-color 19F CSI allows distinction between cells labeled with different PFC compounds in vivo.

Tracking of Human Dendritic Cells in vivo
The final presentation will present data that provides in vivo functional confirmation for the first time that clinically relevant human dendritic cells (DCs) can be effectively labeled in vitro with a 19F tracer without impacting cell health, phenotype, or function while providing a high-resolution image of migratory cells following injection into NOD-SCID mice.

Moreover, the 19F-labeled human DCs are capable of being detected by 19F MRI 8 hours post-injection into NODSCID mice, demonstrating the potential clinical utility for this type of imaging methodology.  This study also demonstrates that transplanted 19F-labeled human DCs can indeed migrate to draining lymph nodes in response to chemokines of a murine host. This novel animal model may now provide researchers with a valuable tool for pre-clinical in vivo human DC studies.

The study involved ex vivo labeling of human dendritic cells using a novel, commercially available fluorine (19F) –based MRI tracer agent (Cell Sense) to visualize these transferred cells in vivo by 19F MRI.

Research for the studies was conducted by scientists at Universität Würzburg Germany, m2m Imaging Corp, Lycera, MIR Preclinical Services, Celsense, Inc, Carnegie Mellon
University, University of Pittsburgh, and the Nijmegen Center for Molecular Life Sciences. 

About Cell Sense
Cell Sense is a fluorocarbon tracer agent used to label cells in vitro then transplanted thus enabling investigators and clinicians to noninvasively track the administration and delivery of therapeutic and diagnostic cells in vivo using MRI.  Applications include tracking therapeutic cells in regenerative medicine and immunotherapy applications, and observing localized immune system response by tracking populations of immune system cells.  Using software developed by Celsense, the investigators can quantify the number of labeled cells in a user-specified region of interest.

About V-Sense
V-Sense is an injectable fluorocarbon MRI tracer agent that labels leukocytes in situ, enabling the direct, non-invasive observation of immune system response and localized inflammation.  Applications include observing change in immune system response to therapeutics and mapping localized disease such as certain cancers and infections.  V-Sense can also be used to detect the partial pressure of oxygen in tissues, an important biomarker in cancer research and treatment

About Celsense, Inc.
Celsense, Inc. (the “Company” and “Celsense”) is an emerging biotechnology company offering novel pre-clinical and clinical-grade molecular imaging agents used to non-invasively visualize and measure biological processes at the cellular level in living systems.  The core innovations of the Company involve molecular imaging agents that can be used to observe the trafficking of cells in small or large animals including humans using magnetic resonance techniques.  The mission of the Company is to establish Celsense as the standard for cellular and molecular imaging in human health research and therapeutics.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com